Breaking New Ground in AML: Practical Applications of Emerging Treatment Options
Chapter 1: New Molecular Abnormalities Recognized in AML
Editor’s Note: Following the filming of this activity, two therapies have received approval by the U.S. Food and Drug Administration (FDA). On August 1, 2017, the FDA granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. On August 3, 2017, the FDA approved CPX-351 for the treatment of adult patients with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Please complete Pre-test
Chapter 1 of 4
ManagingAML.com is pleased to offer “Breaking New Ground in AML: Practical Applications of Emerging Treatment Options.” This activity was previously presented as a live symposium during a clinical oncology meeting held in Chicago, Illinois in June 2017.
If you previously attended and received credit at the live symposium, you are ineligible to receive additional credit for this enduring activity and may not re-submit for credits previously awarded.
Expected time to complete this activity as designed: 120 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity has been developed from a live symposium held in conjunction with a clinical oncology meeting held in June 2017, focusing on the newest advancements in acute myeloid leukemia (AML). Drawing upon both clinical trial data and analysis of case vignettes, a distinguished faculty panel discusses not only new and emerging strategies in the diagnosis, prognosis, and treatment of AML, but also how these critical new advances will change practice in the near future.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe the unmet need resulting from current treatments for AML
- Identify novel therapies and drug combinations being investigated in AML
- Utilize key clinical pearls that will support effective use of novel therapies in patients with AML
New Molecular Abnormalities Recognized in AML – Elli Papaemmanuil, PhD
Current Treatment Paradigms in AML – Richard Stone, MD
Novel Therapies: A Clinical Trial Report – Jeffrey E. Lancet, MD
From Bench to Bedside: Case Studies in AML – Guillermo Garcia-Manero, MD
Instructions for Participation and Credit
This activity is eligible for credit through July 21, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Guillermo Garcia-Manero received his medical degree from the University of Zaragoza, Spain. He completed his clinical internship, residency, and clinical fellowship in hematology and medical oncology at Thomas Jefferson University Hospital, Philadelphia. Dr. Garcia-Manero is Professor and Chief, Section of Myelodysplastic Syndromes (MDS) and Deputy Chair of Translational Research, Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center (UTMDACC) in Houston. In addition, he is Co-Director, DNA Methylation Core, and the endowed Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia, Division of Cancer Medicine, at UTMDACC.
Dr. Garcia-Manero is board certified in medical oncology (hematology eligible), and internal medicine. He holds membership in the American Association for the Advancement of Science, American Society of Hematology, American Society of Clinical Oncology, American Association of Cancer Research (Chair, Scientific Review Committee), Aplastic Anemia and International Myelodysplastic Syndromes Foundation (Steering Committee/Medical Advisory Board), American Medical Association (AMA) Foundation, Society of Hematologic Oncology, and the European Hematology Association. In addition, he is an editor/journal reviewer for numerous peer-reviewed publications. Dr. Garcia-Manero has written more than 800 abstracts, invited articles, and editorials in scientific journals, and is the Principal Investigator in several MDS studies.
Jeffrey E. Lancet, MD
Moffitt Cancer Center
Dr. Jeffrey Lancet is a hematologist at Moffitt Cancer Center and the Department Chair of Malignant Hematology. He focuses his clinical practice in acute leukemias and myelodysplastic syndromes. He also provides consultation for other hematologic malignancies. As a clinical investigator, Dr. Lancet has written, authored and published several early phase clinical trials utilizing novel therapies for these diseases, and currently serves as the principal investigator for many ongoing trials. Within the field of acute leukemias, he has worked extensively with the National Cancer Institute, the Southwest Oncology Group, and the pharmaceutical industry. Dr. Lancet was a recipient of the NCI-ASCO Clinical Investigator Team Leadership Award in 2010.
Elli Papaemmanuil, PhD
Center of Hematological Malignancies
Computational Oncology Service
Department of Epidemiology and Biostatistics
Memorial Sloan Kettering Cancer Center
New York, New York
Dr. Elli Papaemmanuil trained in the UK in population genetics at the Institute of Cancer Research, and in cancer genomics at Wellcome Trust Sanger Center, University of Cambridge, and has led research into the discovery of cancer gene drivers of hematological neoplasms. Dr. Papaemmanuil is a team leader at the Computational Oncology Service, Department of Epidemiology and Biostatistics, at Memorial Sloan Kettering Cancer Center where she is also serving as Associate Director for the Center of Hematological Malignancies. More recently, Dr. Papaemmanuil has developed experimental and analytical methods to support molecular characterization of large patient cohorts and studied the genetic and clinical inter-relationships of leukemias. She currently leads large population genomic profiling studies in myeloid neoplasms (AML, MDS, and MPN) and in acute lymphoblastic leukemia with the aim to characterize how the molecular architecture of the disease and the corresponding clonal relationships determine clinical phenotype and response to therapy, with the aim to deliver patient-tailored diagnostic and risk-stratification algorithms.
Richard Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Dr. Richard Stone received his medical degree from Harvard Medical School, Boston. He completed his internal medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute. He is the Chief of Staff and Director of the Adult Acute Leukemia Program at Dana-Farber, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (a bone marrow failure state that may convert to leukemia).
In addition to his work at Dana-Farber, Dr. Stone serves as Chair of the Medical Oncology Board of the American Board of Internal Medicine, Chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation, and Chairman of the Leukemia Core Committee for the National Cooperative Trials Group the Alliance.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Astellas, Celgene Corporation, Helsinn, Incyte Corporation, and Jazz Pharmaceuticals.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 2.0 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-146-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 2.0 contact hours. Program Number: 17-146-053
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Guillermo Garcia-Manero has disclosed no relevant financial relationships.
Dr. Jeffrey Lancet has received honoraria as a consultant from Bio-Path Holdings Inc., BioSight Ltd., Celgene Corporation, Erytech Pharma, and Janssen Pharmaceuticals, Inc.
Dr. Elli Papaemmanuil has disclosed no relevant financial relationships.
Dr. Richard Stone has received honoraria as a consultant from AbbVie Inc., Agios, Amgen Inc., Celgene Corporation, Fujifilm Corporation, Jazz Pharmaceuticals plc, Novartis AG, Ono Pharmaceutical Co., Ltd., and Orsenix Holdings BV. He has also disclosed a financial relationship with the data safety monitoring board (DSMB): Celgene.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.